Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Open-label Study of Samuraciclib in Combination With Elacestrant in Participants With Metastatic or Locally Advanced Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Breast Cancer

NCT05963997 is registered in ClinicalTrials.gov with Carrick Therapeutics Limited as lead sponsor.

NCT NCT05963997
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05963997 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Open-label Study of Samuraciclib in Combination With Elacestrant in Participants With Metastatic or Locally Advanced Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Breast Cancer
Lead sponsor
Carrick Therapeutics Limited
Phase
Phase 1/2
Overall status
Completed
Start date
October 9, 2023
Completion date
March 6, 2026
Enrollment
49 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, locally advanced breast cancer, metastatic breast cancer